Passive dosimetry (PD) methods for measuring and estimating exposure to agricultural workers (i.e., persons handling agricultural chemicals and working in treated crops) have been in use since the 1950s. A large number of studies were conducted in the 1950s through 1970s to characterize exposure. Since the 1980s quantitative dermal PD methods are used in conjunction with inhalation PD methods to measure whole-body exposure. These exposure or absorbed dose estimates are then compared to ''no effect'' exposure levels for hazards identified in toxicology studies, and have become the standard for risk assessment for regulatory agencies. The PD methods used have never been validated. Validation in the context of human exposure monitoring methods means that a method has been shown to measure accurately a delivered dose in humans. The most practical alternative to isolating parts of the body for validating recovery methods is to utilize field exposure studies in which concurrent or consecutive measurements of exposure and absorbed dose have been made with PD and biomonitoring in the same cohorts of individuals. This ensures that a direct comparison can be made between the two estimates of absorbed dose, one derived from PD and the other from biomonitoring. There are several studies available (published and proprietary) employing both of these approaches. Reports involving 14 concurrent or consecutive PD-biomonitoring studies were quantitatively evaluated with 18 different methods of application or reentry scenarios for eight different active ingredients for which measured human kinetics and dermal absorption data existed. This evaluation demonstrated that the total absorbed dose estimated using PD for important handler and reentry scenarios is generally similar to the measurements for those same scenarios made using human urinary biomonitoring methods. The statistical analysis of individual worker PD:biomonitoring ratios showed them to be significantly correlated in these studies. The PD techniques currently employed yield a reproducible, standard methodology that is valid and reliably quantifies exposure.
Introduction

Historical Perspective on Passive Dosimetry Methods Used to Estimate Farm Worker Exposure and Risk to Pesticides
Passive dosimetry (PD) methods for measuring and estimating exposure to agricultural workers (i.e., persons handling agricultural chemicals and working in treated crops) have been in use since the 1950s and have evolved through refinement of the techniques (Batchelor and Walker, 1954; Durham and Wolfe, 1962; World Health Organization, 1982; Fenske, 1989) . These methods have subsequently been applied to consumers in residential settings. Overall, a large number of studies were conducted in the 1950s through 1970s to characterize exposure. PD, as originally practiced, involved placement of gauze patches on the outside of work clothing in 1-6 body regions to characterize the areas of primary exposure. PD also included ambient air monitoring. Over time the method evolved to placement of patches on and under clothing to estimate the amount of pesticide reaching the skin. Thus, the number of locations was increased to 10 to represent all regions of the body (US EPA, 1986) . In the 1980s the ''whole body'' PD method was developed and became the standard method of measuring dermal exposure in agricultural workers exposed to pesticides (World Health Organization, 1982) . As a result of consider-able research and the long-term acceptance of PD as a method for estimating agricultural worker exposure, these monitoring methods have been codified in international and national regulatory guidelines (OECD, 1997; US EPA, 1997) .
Dermal PD methods are used in conjunction with inhalation PD methods. These exposure or derived absorbed dose estimates can then be quantitatively compared to ''no effect'' exposure levels for hazards identified in toxicology studies. This basic paradigm (hazard identification, doseresponse assessment, exposure assessment, and risk characterization) was summarized by the National Academy of Sciences and has become the standard for risk assessment for regulatory agencies (NAS, 1983 (NAS, , 2006 .
As risk assessment methodology evolved, the concept of a tiered approach to the process applied to agricultural workers was developed (Carmichael, 1995; OECD, 1997) . At its simplest, the tiered approach involves using default upperbound assumptions and generic exposure data (e.g., from the Pesticide Handlers Exposure Database, PHED) for the first and most conservative Tier 1. If further refinement is necessary, Tier 2 utilizes more accurate data for dermal absorption and exposure mitigation factors, for example, for the use of personal protective equipment, alongside the same generic exposure data. The most refined and therefore most accurate Tier 3 involves obtaining chemical-specific exposure data on the pesticide under consideration from either PD or biological monitoring (biomonitoring) field studies. The tiered approach has been used routinely since the 1990s in North America and elsewhere.
Validation of Passive Dosimetry Methods
Validation in the context of human exposure monitoring methods means that a method has been shown to measure accurately a delivered dose in humans. Validation of PD methods by isolating the various components or routes of exposure (e.g., hand wash alone) is very difficult. Such an approach has been successfully adapted to validate inhalation exposure monitoring for gases and vapors in humans (Nomiyama and Nomiyama, 1974) . However, the respiratory system is reasonably localized, whereas the skin covers the entire body. Isolating and validating the recovery from hands or the face/neck, for instance, are much more challenging. Part of the challenge would be preventing contact of the treated hand or face/neck with any other surface for up to 8 h to mimic a normal workday to allow for absorption loss but not redistribution to untreated surfaces. Further, to ensure the ability to monitor and quantitatively recover all of the applied test substance, the active ingredient would need to be radiolabeled.
Even with radiolabel, it may not be possible to account for bound skin residues that are not bioavailable and might take several days to be removed through normal physiologic processes such as loss through sloughing dead skin cells (Thongsinthusak et al., 1999) . In conducting human dermal absorption studies, this problem has been resolved by two methods. One is skin stripping (applying adhesive tape to an area and forcefully removing the tape up to 20 times). This method certainly would not be favorably received by humans, particularly on the face. The alternative method adapted from dermal absorption methodology is to administer the test compound intravenously and determine the fraction of labeled material excreted in urine. This is an indirect way of determining the relative fraction of dose on skin that would be excreted in urine (Feldmann and Maibach, 1974) .
The most practical alternative to isolating parts of the epidermis for validating recovery methods is to utilize field exposure studies in which concurrent or consecutive measurements have been made with PD and biomonitoring in the same cohorts of workers. This method has the advantage of not using radiolabeled material, but rather whatever formulations are in common commercial use. Further, rather than intentionally applying a chemical to human subjects, the exposures described in the following sections have occurred during normal activities associated with pesticide use. In essence, the standard PD method for estimating dermal exposure is modified such that the dosimeters closely represent the normal work clothing and thereby permit the concurrent conduct of the biomonitoring phase. This ensures that a direct comparison can be made between the estimated exposure and the absorbed dose arising from this exposure. These variants of the PD-biomonitoring methods have been described previously by Chester (1993 Chester ( , 1995 and Honeycutt (2000) . In this current paper, the results of the two methods will be compared within each study as a means of validating all of the techniques typically used in a PD monitoring study. The approach also offers opportunities to examine the effect of dosimetry matrix pass through, porosity or bypass, hand wash efficiency, and other questions about the validity of the PD methods.
Biomonitoring, as a means of exposure measurement, is rarely required by government regulatory authorities. Historically, biomonitoring was developed in the fields of occupational medicine and industrial hygiene as an alternative to commonly used PD methods. It offers the best means of accurately assessing human exposure to specific chemicals because it determines actual, rather than potential, absorbed dose (Woollen, 1993) . In the context of exposure to pesticides, Woollen (1993) defined biomonitoring as ''Measurement of a pesticide or its metabolites in the body fluids of exposed persons, and conversion to an equivalent absorbed dose of the pesticide based on the knowledge of its human metabolism and pharmacokinetics''. Biomonitoring is recognized as the ''gold standard'' (Sexton et al., 2004) against which other estimates of exposure can be compared; hence biomonitoring's value in this description of validating PD methods.
Biomonitoring has been used extensively in industrial settings as a measure of exposure and an adjunct with air sampling in hygiene monitoring and surveillance programs to prevent overexposure and ensure compliance with limit values such as the ''Threshold Limit Values'' (TLV) set by the American Conference of Governmental Industrial Hygienists (ACGIH). This organization also sets ''Biological Exposure Indices'' based primarily on urinary biomarkers (http://www.acgih.org/Products/beiintro.htm). During the evolution of PD, biomonitoring was sometimes used as a ''backup'' or insurance method while conducting PD monitoring. In other instances, biomonitoring was used as the primary means of measuring the absorbed dose by integrating all contributions from multiroute exposure, that is, a means for method validation. If it did not produce a perceived or actual improvement in understanding measured exposure, governmental regulators would not request confirmatory biomonitoring studies as they have done, and industry would not perform them because of the great expense and additional time required to develop the supporting pharmacokinetic studies necessary to design and interpret a biomonitoring study.
An important issue in estimating human exposure is to demonstrate that the principal methodology used to generate the exposure data is valid. ''Valid'' in this context means that the exposure methodology is sound, defensible, and capable of a sufficiently accurate estimate of true occupational or residential exposure for eventual use in human health risk assessment. This validation determines if the combined standardized PD methods in their entirety, when used collectively, give a reasonable estimate of the absorbed dose. In this context, validation is not intended for each specific method in isolation, such as patches, whole-body dosimeters, hand washes, face/neck wipes, etc., from the other methods used to determine the dermal and inhalation exposure. One means of validating PD is to compare the absorbed dose estimated by this exposure monitoring methodology with that estimated using biological monitoring.
There are several studies available (some published and some proprietary), which have employed both of these approaches. For the express purpose of validation of PD using biomonitoring, it would be ideal if concurrent measurement data could be compared. This would minimize the uncertainty associated with the assumption that the measured PD exposure is representative of that from the biomonitoring. For example, if PD and biomonitoring were to be measured consecutively in the same workers because of the use of fully interceptive whole-body dosimetry, there would be some degree of uncertainty as to whether the actual exposures of the workers were directly comparable on the two occasions when PD and biomonitoring were conducted. That is to say that more uncertainty exists because it cannot be excluded that the exposures differ for some reason, such as change in behavior, local conditions, or variation in application equipment and associated variables such as amount of product used and application rate. If the exposures differ significantly, then the comparison of absorbed dose via the PD and biomonitoring routes is much more uncertain, because of the potentially different starting points, that is, dermal and inhalation exposure on the two occasions.
A frequently used approach, which has been adopted in the evaluation of most of the studies, is to simply calculate the estimated total absorbed dose by multiplying the PD dermal and inhalation exposure data by appropriate routespecific absorption factors and then summing the resulting dermal and inhalation doses to obtain a total absorbed dose estimate. This PD-based total absorbed dose estimate can then be compared to the estimate of total absorbed dose given by the biomonitoring data. This approach ignores any ''bypass'' of the dermal PD method and assumes that all active ingredients are captured and retained by the dermal dosimeters, including the hand wash and face/neck wipe. It also ignores any contribution of hand-to-mouth contact that might result from use of tobacco products, eating, or poor hygiene while hands are contaminated.
Studies involving concurrent measurement with PD and biomonitoring would most likely have employed partial dosimetry, that is, clothing, to ensure that the biomonitoring is not compromised by use of unrepresentative clothing that workers would not ordinarily wear for the work activities under study. This variant of the whole-body method is described in the OECD guidance document for the conduct of studies of occupational exposure to pesticides (OECD, 1997) . Typically, outer dosimeters would consist of cotton or cotton/polyester long-sleeved shirt and trousers (normal work clothing) and inner dosimeters of T-shirt and briefs (normal underwear). Face wipes and hand washes would be used to estimate the dermal exposure of the face/neck area and hands, respectively. Inhalation exposure would be measured using a relevant personal air-sampling technique in the breathing zone. Several studies of this type are available.
The validation process involves estimating the total absorbed dose arising from all routes of exposure. Using the PD approach, estimated actual dermal exposure (aggregation of estimated penetration of outer dosimeters to underlying skin, handwashes, and face/neck wipes) is adjusted for an appropriate dermal absorption factor, preferably from a human study if available, to give the absorbed dose from the dermal route. The inhaled dose is estimated from the calculated airborne concentration and appropriate ventilation rate for the work activity. The total of the two dose routes gives the combined total absorbed dose estimated from the PD, which could be compared with the total absorbed dose determined through biomonitoring. Equation (1) defines the basis for estimating absorbed dermal dose from PD data. Equation (2) Where ADD is absorbed dermal dose; ODE is outer dermal exposure (from outer dosimeter); CPF is clothing (or outer dosimeter) penetration factor*; DA is dermal absorption factor; IDE is inner dosimeter exposure; ADE is actual dermal exposure (from hand wash and face/ neck wipe); AID is the absorbed inhalation dose; IE is inhalation exposure; IA is inhalation absorption factor (default 100%); TAD is total absorbed dose. * Derived from actual study data on penetration of outer dosimeter to inner dosimeter or based upon penetration data derived from other studies where outer and inner dosimeters have been measured for the same body area.
The purpose of this document is to summarize representative modern exposure monitoring studies for pesticide handlers and reentry exposure and to compare the estimates of dose given by PD and biomonitoring. This document summarizes some recent biomonitoring studies that have been conducted concurrently with PD or consecutively using the same adult subjects for both methods. The estimated absorbed doses using PD are then compared with those given by biomonitoring for the same individuals to determine if there is agreement and to test the hypothesis that PD does not underestimate the absorbed dose. Relevant statistical techniques are used to facilitate the comparisons.
Biomonitoring and passive dosimetry variables
Pesticide biomonitoring studies typically involve collecting urine from individuals (Woollen, 1993) . The urine is analyzed for a compound that is either the parent or a known human metabolite. The kinetics of excretion, preferably in humans, must be known. If this is impracticable, animal kinetics data may be considered; although the greater uncertainty associated with interspecies extrapolation must be recognized (OECD, 1997) . Studies in closely related primate species may also carry least uncertainty in extrapolation. The essential information from the study is the fraction of administered dose excreted in the urine as metabolite(s) and/or parent compound. The basic method for calculating an absorbed dose from biomonitoring data is shown in Eq. (4).
Where AD is absorbed dose and MW is molecular weight. For PD, the absorbed dose is estimated as shown previously in Eqs (1), (2) Over time, a large number of concurrent or consecutive PD-biomonitoring studies have been conducted. Those that did not conform to the criteria outlined above were eliminated from quantitative comparison in the discussion Validation of exposure monitoring methodologies Ross et al. that follows. For example, 34 studies were considered, but 14 studies were accepted for further quantitative comparison. Although the selection criteria eliminated more studies than were accepted for quantitation, the concurrent or consecutive PD-biomonitoring studies summarized in this document represent a wide variety of common exposure scenarios. When the biomonitoring data from these studies are compared with the PD data for the same scenarios, conclusions may be drawn about the representativeness of the central tendency values from PD that have historically formed the basis for regulatory decision-making.
For each study summarized, the data for dermal and respiratory exposure monitoring and total absorbed dosage as well as the absorbed dosage estimated from concurrent biomonitoring were recorded in spreadsheets for each subject. In this way statistical comparisons could be conducted on results from individuals and the central tendency in any given study.
Dermal absorption and pharmacokinetics: key exposure variables
Dermal absorption is a key component of any risk assessment involving a pesticide when the magnitude and temporal profile of a systemically absorbed dose is of concern. With most pesticides, exposure occurs primarily via the dermal route with a minor inhalation component (Wolfe, 1976 ). An accurate measurement of dermal absorption is necessary to estimate dermal absorbed dosage from PD studies for comparison with data from biomonitoring studies. Variables that can affect absorption include exposure time, dose, site of application, formulation, and absorption time. The dermal absorption test species is also a crucial factor. Rat skin, in common with many animal species' skin, is not an ideal model for human dermal absorption. It has been shown to overestimate human dermal absorption by an average of approximately fivefold (Ross et al., 2001) . For the purpose of comparing PD and biomonitoring absorbed doses in this analysis, there was a preference for using human dermal absorption data, if available. Table 1 shows the human in vivo dermal absorption of several pesticides for which there were concurrent or consecutive PD and biomonitoring data.
Because dermal absorption is so important for estimating the absorbed dermal dose from dermal PD data, it is worthwhile to discuss the uncertainties involved in measuring or estimating dermal absorption in humans. First, it is critical to recognize that all of the values listed in Table 1 were derived from human studies, so the uncertainty of animal surrogates is not a concern. Second, all of the in vivo human values were published in the peer-reviewed literature, which lends some credibility to the values reported. Third, when more than one level was tested in humans, the highest dermal absorption value (typically associated with the lowest application rate on human skin) was reported which was most similar to the dose density observed in the PD studies. Finally, for one pesticide (chlorpyrifos), different PD study authors used three widely varying human dermal absorption values. The value shown in column 3 of Table 1 Nolan et al. (1984) ; highest value measured. c Woollen et al. (1992) . d . e Feldmann and Maibach (1974 range of values reportedly used by various studies summarized in this document. Column 2 of Table 1 indicates the single value (3%), which was applied to results from all PD studies summarized in subsequent tables to consistently estimate absorbed dose for chlorpyrifos.
In most cases, human dermal absorption studies were conducted with male volunteers, and the vast majority of biomonitoring studies reported in this document were also conducted with male subjects. Likewise, most human dermal absorption studies were conducted with a wash off of the applied dose after 8-10 h, which is consistent with the upper bound of times individuals were exposed on the job during the biomonitoring studies and reducing (or conservatively overestimating) absorption due to differences in residence time of pesticide on the skin. Because the fraction of applied pesticide that is dermally absorbed is generally inversely related to application (dose) rate, it is important to test absorption at loading doses similar to those incurred by workers during pesticide use (Thongsinthusak et al., 1999) .
Collection of urine must continue long enough to obtain at least three urinary excretion half-lives (88%) to approximate the 90% recovery criterion that EPA requires in metabolism studies (EPA, 1998) . For virtually every biomonitoring study discussed here, this guideline was followed. In some cases, the biomarker was excreted via other routes in addition to urine and some correction must be made for this differential, for example, chlorpyrifos where only 70% is excreted in urine. Finally, the biomarker may represent only a fraction of the parent and some correction must be made for that factor. Listed in Table 1 in the right hand columns are the biomarker (metabolite) name, excretion half-life, and a combined factor that reflects both fraction excreted in urine and fraction of total dose excreted as the biomarker. Data for three of the compounds in Table 1 regarding pharmacokinetics and metabolism were taken from summaries in the exposure monitoring studies, and these numbers were not verified from the original proprietary studies. In the narrative description of each study, there is an indication of duration of urine collection and any departure or other correction from these practices.
Clothing penetration: another key variable
As dose density to outer dosimeters increases, percent clothing penetration decreases resulting in an inverse relationship between challenge and penetration (Driver et al., 2007) . This is consistent with the hypothesis that single-layer clothing percent penetration increases with decreasing outer dosimeter loading or challenge, that is, a higher proportion of the outer dosimeter values appears on the corresponding inner dosimeters, as the outer values decrease. This is consistent with observations made in mammalian dermal absorption studies where the fraction of applied dose penetrating the skin appears to increase at decreasing external dose. This phenomenon is associated with the use of the percent term; in pure quantitative terms, there tends to be more penetration with increasing external loading, although not in direct proportion. The same loading/absorption phenomenon applies to skin, so both dermal loading and dosimeter loading influence variability observed between individuals monitored.
Mean clothing penetration was calculated from 2129 paired inner and outer dosimeters and found to be 8%-12% for whole-body dosimeters (WBD) and patch dosimetry, respectively, from the PHED (Driver et al., 2007) . Thongsinthusak et al. (1993) summarized results from a number of other exposure monitoring studies that support this observation. An average clothing penetration value of 10% was used in two exposure monitoring studies where clothing penetration could not be estimated from study data (Grover et al., 1986; Findlay, 1998) . This value was considered conservative, because in most studies whole-body dosimetry or some variant was used, and in most cases there was substantial concentration on the outer dosimeter. Further supporting the conservatism of this default is the fact that the measured clothing penetration as recorded in Table 2 was consistently o10%.
Biomonitoring and passive dosimetry study summaries
Narrative summaries of study design are provided for those studies for which there were quantifiable PD and biomonitoring results for a majority of study participants. The preponderance of quantitative data was derived from nine studies ( Tables 2 and 3) (Table 2 ). All workers wore a minimum of an outer coverall over a short-sleeved shirt, long pants, underwear, socks, and boots. The underwear (T-shirt (2008) 18(2) and briefs) was used as inner dosimeters, whereas coveralls were used as outer dosimeters. Additionally, workers wore helmets, a respirator, goggles, and chemical-resistant gloves. Inhalation exposure was monitored using a personal air pump with a flow rate of 1-2 l/min through a cassette with a pre-filter followed by Chromosorb 102 sorbent. The workers were assumed to breathe at 1.5 m 3 /h. Face and neck exposure was estimated based on two 4 00 Â 4 00 patches placed on the helmet. Urine was collected from each worker 1 day before use and for 4 days after handling chlorpyrifos. Urine was analyzed for 3,5,6-TCP. Workers in each work category were examined for pre-study TCP levels greater than postexposure TCP levels, and those replicates were excluded from further consideration.
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Open-Pour Aerial Mixer/Loader (Knuteson et al., 1999) Fifteen workers mixed and loaded Lorsban 4E for aerial application. The study was conducted in Texas and Arizona. Each worker opened, pierced the foil seal of, emptied, and rinsed 25-50 jugs containing 2.5 gallons each. After open pouring the Lorsban 4E into the mix tank and adding water, each worker transferred the contents to planes via hose. Each worker mixed and loaded sufficient chlorpyrifos to cover approximately 500 acres. Workers Data also quoted in terms of mg/lb a.i. because 2 or 3 days of product use were monitored, during which PD was used on two occasions and biomonitoring covered the 3 days continuously. Consequently it is considered feasible to express the data in this way because it is difficult to ascertain the daily absorbed dose of atrazine from the composite biomonitoring data.
Validation of exposure monitoring methodologies Ross et al. wore a coverall over underwear, goggles, a cap, a chemicalresistant apron, boots, and gloves. The underwear (T-shirt and briefs) was used as inner dosimeters, whereas coveralls were used as outer dosimeters. Inhalation exposure was monitored using a personal air pump with a flow rate of 1-2 l/min through a cassette with a pre-filter followed by Chromosorb 102 sorbent, and workers were assumed to breathe at 1.5 m 3 /h. Urine was collected from each worker 1 day before use and for 4 days after handling chlorpyrifos. Urine was analyzed for 3,5,6-TCP. The pre-exposure (background) TCP levels were subtracted from the daily post-exposure analyses for TCP. Four of 15 replicates were not used in this study due to confounding caused by preexposure or post-exposure urinary metabolite concentrations.
Groundboom Mixer/Loader, Applicator, Reentry Scout Exposure (Shurdut et al., 1993) Nine applicators were monitored during groundboom application of chlorpyrifos to low crops using open-cab tractors in Michigan, Arizona, and Florida. Each applicator handled 27-330 lb active ingredient (AI). Nine M/L used either Lorsban 50W or 4E. Ten scouts were monitored in Arizona and Florida 24 h postapplication. M/L and applicators wore coveralls over underwear, socks, baseball cap, goggles, and chemicalresistant boots. M/L that handled Lorsban 50W also wore half-face respirators equipped with particulate filters and organic vapor cartridges. Scouts wore T-shirt and briefs, closed toe footwear, baseball cap, and coveralls with sleeves cut off above the elbows. Sweatbands served as forearm dosimeters. Concurrent PD consisted of underwear (T-shirt and briefs) used as inner dosimeters, whereas coveralls were used as outer dosimeters. Inhalation exposure was monitored using a personal air pump with a flow rate of 1-2 l/min through a cassette with a pre-filter followed by Chromosorb 102 sorbent, and workers were assumed to breathe at 1.5 m 3 /h.
Urine from applicators was taken 1 day before and for 5 days after application. Urine was analyzed for 3,5,6-TCP. (Table 2 ). All workers wore a minimum of an outer coverall over a shortsleeved shirt, long pants, underwear, socks, and boots. The underwear (T-shirt and briefs) was used as inner dosimeters, whereas coveralls were used as outer dosimeters. Additionally, they wore baseball caps. Inhalation exposure was monitored using a personal air pump at a flow rate of 1 l/min through a cassette with a pre-filter followed by Chromosorb 102 sorbent, and workers were assumed to breathe at 1.5 m 3 /h. Urine was collected from each worker 1 day before use and for 4 days after handling chlorpyrifos. Urine was analyzed for 3,5,6-TCP.
Citrus Pruners and Harvesters (Honeycutt and Day, 1993 ) Fifteen reentry workers, 10 pruners, and five harvesters were monitored while reentering chlorpyrifostreated citrus after airblast application in California. Workers contacted treated foliage for at least 6.2 h per day (Table 2 ). All workers wore a minimum of an outer coverall over underwear, socks, and tennis shoes. Additionally, the harvesters wore short-sleeved shirt, and long pants under the coveralls due to cold weather. The underwear (T-shirt and briefs) was used as inner dosimeters, whereas coveralls were used as outer dosimeters. Additionally, they wore baseball caps, forearm gauntlets of canvas and cotton or canvas gloves. Inhalation exposure was monitored using a personal air pump with a flow rate of 1 l/min through a cassette with a pre-filter followed by Chromosorb 102 sorbent, and workers were assumed to breathe at 1.5 m 3 /h. Urine was collected from each worker 1 day before reentry and for 4 days after contacting treated foliage. Urine was analyzed for 3,5,6-TCP, and the higher value of either the kinetic or stoichiometric method was used to calculate exposure. Replicates in each work category were examined for pre-study TCP levels greater than post-exposure TCP levels, and those replicates were excluded from further consideration. Harvesters had no detectable residues on the inner dosimeters, so half the limit of detection was assumed for estimating dermal exposure.
Hose-End Sprayers and Hudson Sprayer (Rosenheck, 2000) This PD-biomonitoring study involved the consecutive evaluation of PD and biomonitoring. Exposure was determined using the PD approach, followed by a biomonitoring phase in which the same individuals made further applications approximately 5 days later. Individuals within a handler scenario were monitored first using cotton long johns worn under short-sleeved shirt and short pants, and the same individuals within a use scenario were subsequently biomonitored without long johns. Three methods of application frequently used by homeowners were monitored:
Hose-end sprayer with a ready-to-use (RTU) formulation; 11 handlers. Hose-end sprayer with an emulsifiable concentrate (EC) formulation; 12 handlers. Hudson pump-up type hand sprayer with wand; 10 handlers.
Each person using hose-end sprayers applied 0.5 lb of AI of diazinon in a 946-ml container to approximately 5000 square feet of turf. Hudson sprayer users mixed, loaded, and applied 0.021 lb AI of diazinon in an EC formulation to house perimeters, spot lawn treatments, ornamentals, and shrubs. Volunteer each wore a T-shirt, shorts, socks, and shoes. All monitoring was conducted in North Carolina in 1999, and replicate duration was 18-122 min, depending on method of application. Urine was collected for 1 day before and 4 days after use; it was analyzed for 6-methyl-2-isopropyl-4-pyrimidinol (G-27550), a diazinon-specific metabolite.
Groundboom Applicators and Mixer/Loader/Applicators (Selman, 1996) Groundboom applicators (n ¼ 7), mixer/ loader/truck tenders (n ¼ 8), and M/L/A (n ¼ 4) were biomonitored for urinary metabolites after use of atrazine on corn in the Midwest. The workers in the study handled between 148 and 3450 lb atrazine over a 3-day monitoring period during the early part of the pre-corn planting period during which the product is typically applied. The biomonitoring phase consisted of collection of urine samples on at least 1 day before being monitored and during each day of atrazine use over the 3 days of monitoring. Replicate analyses of PD were conducted on the same workers on the first and second days, and the results averaged by worker. The metabolite excretion data were adjusted for the fraction of dose excreted as chlorotriazines in humans to estimate the atrazine-absorbed dose. Workers wore long-sleeved shirts, long pants, and occasionally a sweatshirt in cold weather. The inner dosimeters consisted of 100% cotton T-shirts and 100% cotton briefs. Hand exposure was measured using a 0.01% Aerosol OT hand wash followed by a distilled water hand rinse. Head and neck exposure was estimated using two patches attached to a baseball cap. Inhalation exposure was measured using a filter and vapor collection tube attached to a personal airsampling pump.
Groundboom Mixer/Loader/Applicators (Chester et al., 1989) Fourteen vehicle groundboom M/L/A were monitored concurrently with PD and biomonitoring during use of fluazifop-p-butyl in the Netherlands. They handled, on average, 7.2 kg (3.8-14.6 kg) (15.8 lb (9.5-32 lb)) fluazifop-P-butyl during a typical day's use of the product in field crops. They wore standardized dosimeters consisting of 100% cotton coveralls over cotton T-shirt and socks. Soap and water handwashes were performed whenever the subjects wanted to wash their hands. There was additional wearing of sweatshirt (pullover) and pants by three subjects during colder weather. Inhalation exposure was not measured because this was assumed to be negligible for hydraulic groundboom application of an insignificantly volatile compound. Eight subjects complied with the label requirement for use of the chemical-resistant gloves; none of the subjects elected to wear the label-required safety goggles, although one wore a faceshield. Twenty-four hour urine samples were collected from all subjects for a total of 11 days, including the day before the use of the product. Urine aliquots were analyzed for the metabolite fluazifop and creatinine as a check on the completeness of collection.
Backpack Mixer/Loader/Applicators (Findlay, 1998) Twenty M/L/A were monitored concurrently with PD and biomonitoring during use of diquat with hand-held backpack sprayers in banana plantations in Guatemala. The amounts of diquat handled ranged from 0.29 to 0.38 kg (0.64-0.84 lb) during a typical day's use. Standardized dosimeters were used consisting of 100% cotton long-sleeved shirts and trousers. A soap and water handwash method was used to measure hand exposure whenever the subjects wanted to wash their hands so as not to interfere with the biomonitoring phase. Inhalation exposure was measured using Institute of Occupational Medicine (IOM) inhalable fraction samplers attached to personal sampling pumps worn by the subjects. Protective gloves and faceshield were provided for use during mixing and loading the product in accordance with the product label recommendation, with which there was generally good compliance. Twenty-four hour urine samples were collected by each subject over a 7-day period, including the day before the day of use of the product. This period was based on the urinary elimination half-life determined in a human volunteer dosing study. Aliquots were analyzed for unchanged diquat and creatinine as a check on completeness of urine collection.
Data from the biomonitoring studies summarized above are shown in Tables 2 and 3 . It is important to note that the data from some of the biomonitoring studies (e.g., Chester et al., 1989; Honeycutt and Day, 1994; Knuteson et al., 1999) contain results from individuals whose work practices were apparently less careful than other individuals in these studies (or had verified accidents) resulting in much higher exposures on one or more body regions relative to other members of their cohort. Results from those individuals were included in the geometric mean values shown in Table 3 , even though they represent the upper extreme for those scenarios monitored. Additionally, there were studies in which individual handlers appeared to have no exposure (i.e., their post-handling excretion of the analyte was less than prior to exposure) such as Knuteson et al. (1999) and Shurdut et al. (1993) . These values were excluded as unrealistically low, and were probably due to work exposure shortly before the study. The concurrent PD from those individuals was also excluded, so that there was always the same number of PD and biomonitoring results in a given study. By retaining highly exposed individuals, it tested the limits of the comparison of PD to biomonitoring.
Dermal Passive Dosimetry Extrapolation to Whole Body
Two primary methods of dermal PD in conjunction with biomonitoring were utilized in the studies summarized in Tables 3, 5 and 6. All of the dermal exposure estimates in Tables 3 and 5 included hand wash and a face/neck wipe or head patch to estimate face/neck exposure. The most straightforward sampling method to test exposure was concurrent PD and biomonitoring, but an alternative was where the same individual or group was tested consecutively. For example, Rosenheck (2000) used WBD under typical residential clothing (short-sleeved shirt and short pants) to measure exposure that would have occurred to bare lower legs and arms, and under a single layer of clothing to assess pesticide that penetrated or was not covered by typical residential clothing, and a few days later biomonitored the same individuals wearing only residential clothing without WBD. A variant of this method used co-located individuals wearing a single layer of WBD or a bathing suit to measure exposure to the same treated carpet, and both groups were biomonitored . A completely different design used in several studies involved concurrent PD and biomonitoring in the same individuals all of whom wore normal work clothing over T-shirt or T-shirt and briefs (Chester et al. 1989; Honeycutt and Day, 1993, 1994; Shurdut et al., 1993; Selman, 1996; Murphy et al., 1998; Knuteson et al., 1999) . Scenario-specific clothing penetration was assessed by taking the ratio of residues measured on the T-shirt to residues on the work shirt minus lower arms. This clothing penetration factor was then applied to body areas covered by a single layer of clothing (e.g., lower arms or legs), and that dermal exposure was added to exposure measured on T-shirts and briefs, face and hand washes to obtain total dermal exposure. No attempt was made to Only replicates where post-application exposures were greater than pre-application based on biomonitoring were used. The first number indicates the number of replicates used, the second is the number of replicates actually monitored.
b Geometric mean absorbed dermal dosage derived by applying dermal absorption factor from Table 1 . c Geometric mean inhalation dosage based on respiratory protection (if used) and assuming 100% uptake and retention. 
Published Studies Involving PD and Biomonitoring Measurements of Exposure
Open-Pour Groundboom Mixer/Loader/Applicator (Grover et al., 1986 ) Eight farmers in Saskatchewan applied 2,4-D while wearing two layers of cotton clothing. Patches were placed underneath the clothing to estimate dermal exposure to covered areas and an outer chest and back patch were used to estimate exposure to face and neck. Hands were washed once at the end of the day with a sodium bicarbonate solution. Total urine output was collected from each participant for 4-7 days post exposure. One of the eight replicates was excluded (subject F) due to an unrealistically high (1.7 g) dermal exposure that apparently was attributable to one of the outer dosimeters and had no corollary high biomonitoring output.
Open-Pour Groundboom Mixer/Loader/Applicator (Chester and Hart, 1986 ) Thirteen subjects were monitored consecutively using biological monitoring and then PD during mixing, loading, and application of fluazifop-butyl with vehicle-mounted groundboom application equipment in Canada. Three other subjects were also monitored during mixing and loading only. Their data are not included in this assessment because PD was conducted only during the first, interim, and final mixing/loading, and so the data are not directly comparable with the biologically monitored absorbed dose. The subjects each handled approximately 132 lb active ingredient during application to approximately 300 acres. The biological monitoring phase was conducted first, involving collection of 24-h urine samples for 9 days, including the day before use of the product. Aliquots were analyzed for the major metabolite fluazifop. The absorbed doses of fluazifop-butyl were estimated using the human pharmacokinetic data described previously. The potential and actual dermal exposures were measured using synthetic ''Tyvek'' coveralls incorporating a hood, and gloves as dosimeters. Inhalation exposure was not measured because it was considered to be negligible for a compound of low volatility applied with hydraulic application equipment. The biological monitoring absorbed dose data for subject number 1 were excluded from the comparison because it was known that he had provided incomplete urine samples.
Published Post-Application Exposure Monitoring Studies Conducted with Concurrent PD and Biomonitoring
In addition to pesticide handler exposure monitoring studies, there are numerous published post-application exposure monitoring studies conducted with concurrent PD and biomonitoring. These studies started as early as 1954 with apple harvesters (Batchelor and Walker, 1954) , but reliable studies where the whole body was adequately represented by the patch dosimetry configuration recommended by EPA's 1986 guidelines did not occur until the 1980s. Beginning in the 1990s several concurrent PD and biological monitoring studies have also been conducted as summarized in Table 6 .
Several studies have been conducted using structured activity (e.g., Jazzercise) in which volunteers participated in aerobic exercises on a treated surface for intervals of approximately 20 min (Ross et al., 1990 (Ross et al., , 1991 . None of these studies have monitored individual inhalation exposure, and in the case of chlorpyrifos, it has been demonstrated that Only replicates where post-application exposures were greater than pre-application based on biomonitoring were used. The first number indicates the number of replicates used, the second is the number of replicates actually monitored.
b
The estimated absorbed dose from passive dosimetry was the value estimated for a whole body and divided by body weight. c Value from previous column multiplied by dermal absorption fraction. Whole-body exposure was estimated using the value for (sock divided by 0.12, fraction on sock from Ross et al., 1990; Selim and Krieger, 2006) divided by average participant body weight. e Dosimetry garments included gloves, socks and long johns. Validation of exposure monitoring methodologies Ross et al. inhalation exposure potential during the 20 min of surface contact is negligible (i.e., with maximum air concentrations of 14 mg/m 3 (Ross et al., 1992) , the exposure from inhalation would constitute B0.1 mg/kg assuming a breathing rate of 29 l/min and 100% uptake and retention). In the studies summarized here, volunteers either wore dosimetry clothing and were concurrently biomonitored or individuals were monitored side by side (a cohort wearing dosimetry garments and another wearing minimal clothing). Following are short narrative descriptions of those studies accompanied by Table 6 that summarizes results from this genre of studies.
Williams et al. (2003)
A commercial formulation of cyfluthrin was broadcast applied using a calibrated wheeled system to the surface of nylon carpet and allowed to dry. Seven male volunteers wore a single cotton sock and cotton shorts and participated in a structured activity program (Jazzercise). Following exposure, the participants provided the sock and shorts for extraction and analysis. Only the socks were used for quantifying dermal dose. Whole-body exposure was estimated using the value for a sock divided by 0.12 which represents the fraction on a single sock from several WBD studies (Ross et al., 1990; Selim and Krieger, 2006) , and this value was divided by average participant body weight of 85 kg. They also collected their urine 12 h pre-exposure and 72 h post-exposure. Urine was analyzed for the biomarker, 4-fluoro-3-phenoxybenzoic acid.
Krieger et al. (2000)
Total release foggers containing 1% chlorpyrifos were applied to nylon carpet indoors. Two groups of volunteers (one group of 13 wearing cotton WBD and the other group of 21 wearing bathing suits) reentered the room after a 2-h drying interval. Each group exercised on the treated carpet using Jazzercise. The WBD were collected and analyzed for chlorpyrifos. Both groups provided 24-h pre-exposure and 72-h post-exposure total urine collections. Urines were refrigerated during the 24-h collection intervals and were analyzed for TCP. This study design allowed for testing penetration through WBD by clearly demonstrating an increase in excretion over pre-exposure. The ratio of biomonitored dose for individuals wearing WBD to those wearing minimal clothing gives a good indication of penetration through a single layer of WBD (15%) and is consistent with the value assumed for other studies not using both inner and outer dosimeters.
Williams et al. (2004)
A mobile spray cart was used to uniformly apply 0.5% formulated chlorpyrifos to new nylon carpets. While carpets dried, 21 volunteers wearing one cotton sock and cotton shorts were randomly assigned to two groups. One group was allowed to sit and rest, whereas the other group performed aerobic Jazzercise in an untreated area to induce sweating. At this point, both groups performed a low impact Jazzercise routine on the treated carpet. Following the surface contact, each participant provided the socks and shorts for analysis of chlorpyrifos. Only the socks were used for quantifying dermal dose. Whole-body exposure was estimated using the value for sock divided by 0.12 which represents the fraction on sock from several WBD studies (Ross et al., 1990; Selim and Krieger, 2006) . Complete urine was collected 12 h before exposure and through 5 days postexposure and analyzed for TCP. Following a 2-week hiatus, volunteers participated in a crossover design in which the resting participants were those who had previously sweated and vice versa. Samples were collected as in the first part of the study.
Exclusion of Proprietary and Published PD-Biomonitoring Studies from Quantitative Evaluation
Of studies reviewed, a large number could not be used for a quantitative comparison of biomonitoring to PD. Although these studies provide valuable measurements of compoundspecific exposure, each one lacked either measurable levels in the biomonitoring component or PD component needed to estimate whole-body dose. The basis for the exclusion criteria recommendation for studies with human/primate dermal absorption o1% was a practical recognition of the difficulty in establishing a validated LOQ that is sufficiently low to allow consistent detection (i.e., so that a majority of urine samples taken 1-2 days post-exposure would have quantifiable levels). Several studies were examined that helped confirm this criterion. Some of those studies are listed in Table 7 because estimates of dosage from biomonitoring based on half the LOQ would substantially exceed the estimated PD dosage; therefore actual metabolite presence in urine was questionable. Examples include Wojeck et al., 1983; Chester et al., 1991; Cowell et al., 1991; Lavy et al., 1992; Krieger et al., 1996; Findlay and Wiseman, 2000. Some published studies on occupational paraquat exposure involving concurrent PD and biomonitoring were excluded primarily because the urinary concentrations of paraquat were less than the LOQ (e.g., Wojeck et al., 1983; Chester et al., 1993) . The point of these observations is that the analytical sensitivity determines whether the absorbed dose estimated via PD is less than, greater than, or equivalent to the biomonitoring dose estimated by use of half the LOQ and urine volumes. Other studies (e.g., Staiff et al., 1975; Forbess et al., 1982) were not included in Table 7 because their urine LOQ was too high to measure the dose measured by passive dosimeters. In another example, the urinary LOQ was adequate, but failed to consistently measure exposure in the 2 of 11 workers who had detects (van Wendel de Joode et al., 1996) .
Most of the studies listed in Table 7 were older (1980s and early 1990s) and were conducted with patch dosimetry. It has been hypothesized that patch dosimetry will tend to overestimate dermal exposure more than WBD (Ross et al., 2001 ) for a variety of reasons. However, to our knowledge, there has been no definitive two-cohort (side by side) or concurrent patch and WBD study conducted to test the hypothesis. Chester and Ward (1983) conducted a study to examine the concordance of patch dosimetry and WBD done concurrently. Results of that study show that in two of three scenarios, the results are comparable, but in one, the patch dosimetry grossly underestimates results from WBD. Moreover, in general it has been shown that the patch dosimetry data from PHED tends to overestimate absorbed dose estimates obtained from biomonitoring using the same pesticide handling equipment and formulation type (Ross and Driver, 2006) . For this reason and others (some evident While these studies do not have all of the attributes necessary to make a valid comparison between PD and biomonitoring, they may represent the best data available for individual pesticide exposure assessments.
Validation of exposure monitoring methodologies Ross et al. in Table 7 ) related to the age of the patch studies, these older studies may be useful to support an hypothesis or be used in the absence of more recent data, but should not be relied upon in preference to more recent, higher quality data. Further, as pointed out by Chester and Ward (1983) and Fenske (1990) , dermal deposition over a body region represented by a patch is not uniform and patch placement to optimally capture exposure varies between work activities.
Other older studies similarly using patch dosimetry, hand washes, and air monitoring have demonstrated that PD overestimates biomonitoring with pesticides having diverse physicochemical properties such as alachlor (Dubelman and Cowell, 1989) , EPTC (Knaak et al., 1989) , and malathion (Fenske, 1988) . Despite exclusion from quantitative comparison of PD versus biomonitoring of a number of published and proprietary concurrent PD/biomonitoring studies shown in Table 7 , for the most part these studies also support the hypothesis that PD does not underestimate biomonitoring. Among those excluded studies was a potentially relevant work by Fenske (1988) that involved concurrent PD with patches placed per Subdivision U on the outside of clothing and biomonitoring for M/L and applicators making airblast applications of malathion to citrus. Because individual data for each handler were not published it was not possible to analyze these data in the same manner as other studies discussed here. Further, because the dermal data were not normalized to body surface area represented by each patch and all locations were not included in the data calculations, the data were incomplete. Despite these limitations, the study's author did find statistically significant correlations between patches and biomonitoring.
Validation methods
The purpose of this section is to describe the possible ways in which validation of PD with biological monitoring may be accomplished. Occupational or residential exposure to pesticides during use and reentry into treated areas for specific activities can be measured using PD and biological monitoring concurrently or consecutively in the same individuals and results compared.
Statistical Treatment of PD/Biomonitoring Data
Typically, exposure monitoring results tend to be distributed log-normally (Kromhout and Vermeulen, 2001 ), so it is more convenient to analyze data that have been log-transformed. Because arithmetic means on the log scale easily backtransform to geometric means on the original scale, the reporting of results in terms of geometric means is also convenient.
With the unique studies under examination in which PD and biomonitoring have been conducted concurrently, the most appropriate comparison between methods is their difference on the log scale. Differences on the log scale are equivalent to ratios on the untransformed scale. When each individual has both a PD and a biomonitoring measurement then it is appropriate to consider the individual mean logscale differences between the two measurements. For any group of individuals, the group mean of log-scale differences is the same as the difference between log-scale group means. Thus, on the log scale, the result is the same whether one refers to mean differences or differences of means. There is a similar equivalence between ratios and geometric means. Namely, the result is the same whether discussing the geometric mean of individual ratios or the ratio of geometric means.
The critical point is that although final results may be summarized in terms of group geometric means, it is still the individual ratios (or log ratios), which are relevant to the statistical analyses. In this particular case, the influence of any individual exposure (whether low or high with respect to the population mean) will have a direct corollary in the concurrent exposure measurement. Thus, if the measure of dermal exposure is high for a particular individual, one would expect if the PD method reflects true exposure that the corresponding absorbed dose measurement for the biomonitoring component would also be high. The key question is whether PD is representative of the absorbed dose determined through biomonitoring across a variety of exposure scenarios.
Comparisons of PD-determined and biomonitoring-determined total absorbed dose
The results obtained from the 14 concurrent PD and biomonitoring studies were used to investigate the association between the PD-absorbed dose and the biomonitoring absorbed dose measured from the same individual. Figure 1 shows that although there is considerable variation, the two estimates of total absorbed dose are strongly correlated. The correlation between the logarithms of TAD PD and TAD biomonitoring is 0.653 (Po0.0001). The Spearman rank correlation (Conover, 1999) between untransformed TAD PD and TAD biomonitoring is 0.672 (Po0.0001). Because both absorbed doses are measured with error, simple regression of one on the other would be inappropriate because it would yield slopes that are biased towards 0. The diagonal line in Figure 1 is for visual reference only.
Because the simple correlation shown in Figure 1 ignores much of the structure present in the data, the significance levels of the correlation coefficients should be considered only approximate. An analysis that more closely accounts for this structure is one that recognizes that these individual data are grouped into studies and, in some cases, scenarios (e.g., ''tasks'') within study. This structure is detailed in Tables 3, 5 and 6 and also in Figure 2 where the individual PD/biomonitoring ratios are shown grouped by study and scenario. Separate scenarios are grouped side by side and studies are arranged in chronological order of the reference.
The following variance components, or hierarchical model (West et al., 2004) were used to estimate the geometric mean PD/BM ratio:
Here, R ijk is the PD/biomonitoring ratio for individual k of scenario j in study i. The terms A i , B ij , and C ijk , represent random (and normally distributed) sources of variation coming from studies, scenarios within studies, and individual exposures within scenarios, respectively. The MIXED procedure in Version 9.1 of SAS (2004) was used to fit Eq.
(5) to these data. GM in Eq. (5) should be interpreted as the true geometric mean ratio over all studies and scenarios. It is a measure of overall bias between the two estimation methods. A ratio of 1 indicates equivalence, on the average, of the two methods. The solid black line in Figure 2 is the overall geometric mean ratio (1.18) obtained from the analysis. The shaded area indicates the 95% confidence interval for the true geometric mean (0.67, 2.1). Because this interval includes one (the dashed line), there is no evidence of any overall bias in the PD-derived absorbed dose compared with that derived from biomonitoring.
In addition to the geometric mean and confidence interval, this analysis also estimates the relative magnitude of the three sources of random variation in Eq. (5). A substantial portion of the variation in individual PD/biomonitoring ratios (38%) comes from differences between studies. Variation between replicate individuals accounts for most of the remaining variation (56%). Only 6% of the variation in PD/ biomonitoring ratios comes from differences between the scenarios within a study. This is consistent with the variability seen in Figure 2 .
The between-individual variation is probably reflecting the ''background'' variation that would always be encountered regardless of any bias in PD-absorbed dose estimates. It is a combination of individual differences and measurement variation in both PD and biomonitoring doses. It also includes any within-study structure that may not be completely accounted for by the variance component model in Eq. (5). The strong study-to-study differences, however, suggest that any given study could have strong biases in PDabsorbed dose relative to the biomonitoring absorbed dose. However, such biases do not appear to systematically favor either PD or BD. Such a pattern is commonly observed when there are study-specific imperfections in various ''adjustments'' made (e.g., in this case to estimate absorbed dose). Study-specific biases in the analytical processing could also be a contributing factor. In any event, this study effect appears to operate the same on all individuals in a particular study, regardless of the scenario monitored.
Association of PD/biomonitoring ratio with study dermal absorption values
The individual ratios obtained from the same 14 studies were used to investigate the association between the PD/biomonitoring ratio and the dermal absorption factor used in Chester & Hart, 1986 Grover et al, 1986 Chester et al, 1989 Honeycutt, 1993 Shurdut, 1993 Honeycutt, 1994 Selman & Rosenheck, 1996 Findlay, 1998 Murphy, 1998 Knuteson, 1999 Rosenheck, 2000 Williams, 2003 Williams each study (Table 1) . This was done using a mixed-model linear regression (West et al., 2004) of log PD/biomonitoring ratio on dermal absorption. That is:
Source
As in Eq. (5), R ijk is the PD/biomonitoring ratio for individual k of scenario j in study i. DA i denotes the dermal absorption factor used in study i. The intercept and slope of the regression line are just a and b, respectively. As before, A i , B ij , and C ijk , are terms necessary to account for random study, scenario, and replicate effects, respectively. The MIXED procedure in Version 9.1 of SAS (2004) was used to fit model (6) to these data.
The results of this regression are summarized in Figure 3 . There is no significant linear trend (P ¼ 0.9030) and the regression line is almost coincident with the overall geometric mean of 1.18 estimated previously (the dashed line in Figure 3 ). Consequently, there is no evidence in these data that the PD/biomonitoring ratio is systematically associated with the dermal absorptions assumed in the particular study.
Insignificance of the Dosimetry ''Pass Through'' Component of Exposure
Despite the outer and inner dosimetry, and occasionally use of impermeable gloves, there might be a still measurable biomonitoring dose that exceeds the IE. If the biomonitoring actually measures an absorbed dose, then this biomonitoring dose must have been in part absorbed despite the presence of the partial dermal dosimetry and so was not captured or intercepted by it. It could only have arisen through dermal or inhalation absorption, or incidental oral ingestion. Should part of the biomonitoring dose be factored back into the PD exposure estimate to give a more precise value for the express purpose of comparing the estimates of absorbed dose given by the two methods? The OECD guidance document states that estimates of actual dermal exposure in the variant of the whole-body method should include the dose estimated to have been absorbed dermally (OECD, 1997). The decision depends upon the work activity and whether the dermal route is significant or perhaps the predominant route of exposure and absorption, for example, for vehicle groundboom hydraulic downward application. The concurrently measured dermal biomonitoring dose could have arisen through:
Penetration via the outer dosimeter to underlying skin not covered by an inner dosimeter, for example, lower legs or forearms; Penetration via the outer dosimeter though a T-shirt to underlying skin, for example, torso; Absorption via the hands in-between serial hand washes, or from residual material on the hands not removed by the hand wash; Absorption via the face/neck area similar to the hand wash issue above.
At least some of the uncertainty of ''dosimeter pass through'' was eliminated in the older PD studies where foilbacked patches were used, because with this configuration, the full amount of both outer and inner dose was fully intercepted.
The biomonitoring dose resulting from hand, face/neck or body parts covered by dosimeter clothing: biomonitoring TAD -AID (AID derived from IE measurement), could be added to the measured dosimetry clothing dermal exposure value. The distribution of dermal exposure indicated by the dermal PD might provide insight into the relative contributions of the different body sites to total actual dermal exposure.
Inclusion of the biomonitoring dose fraction attributable to absorption from skin areas covered by outer dosimeters in the estimate of total dermal exposure may be necessary because the porosity of the dosimetry clothing is frequently greater than the dermal absorption of the active ingredient, thereby leaving residual active ingredient on the skin surface beneath the outer dosimeter. This dermal exposure is the partial source of the biomonitoring dermally absorbed dose and is not captured or intercepted by the partial inner clothing PD.
If the hand wash data indicate that hands are a significant contributor to dermal exposure and thus absorption, inclusion of the biomonitoring dose fraction attributable to absorption from the hands in the estimate of total dermal exposure is also necessary. The key difference between the body areas washed and those covered by dosimeter clothing is that the hand and face are typically directly exposed.
An estimate of dosimetry garment pass through can be derived as follows: Given the relative uncertainties all possible means of validation of PD with biomonitoring were investigated using the data available, in the ways described above. However, regarding the dosimetry pass through issue, it is clear from examining Figure 2 or 3 that about half of the data points lay below the line, suggesting that there may be a component of pass through. On the other hand, half lay above the line that would give negative numbers for pass through. Further complicating this approach is that for some data, the inhalation component alone exceeds the biomonitoring dose. Overall, these data suggest that dosimetry pass through is not a significant issue. Two concurrent PD: biomonitoring studies conducted with only a single outer dosimetry layer allow one to calculate the ''pass through'' that occurs through whole body dosimetry garments and it falls in the range of 8%-15% (Findlay, 1998; , which is basically the same range measured for clothing penetration in many other PD studies (Driver et al., 2007) .
Conservative Biases in both Passive Dosimetry and Biomonitoring
Contributing to conservatism (tendency to overestimate exposure) in the PD studies was the practice of taking the simple ratio of inner to outer dosimeters as an estimate of clothing penetration (e.g., Shurdut et al., 1993 and a majority of the other studies where it was utilized) rather than the more rigorous (and correct) method of dividing the inner dosimeter residue by the outer plus inner residues. The net difference between these two methods is typically o10%.
It is noteworthy that inhalation dosimetry as frequently interpreted by regulators tends to be upper bound. Several studies reviewed here used the old default value of 29 l/min respiration rate. However, inhalation data from all studies were normalized to a respiration rate of 16.7 l/min. In some cases, the inhalation exposure exceeded the exposure estimated from biomonitoring, even when results were adjusted for physiologically compatible respiration rates.
Another point worth mentioning is that the dermal absorption factor usually applied to M/L/A exposure data is that defined for the dilute spray material, that is, the higher percent value derived from a relevant dermal absorption study. This is done in the interests of conservatism and also because it is not possible to distinguish the relative contributions from exposure to the concentrated formulated product and the diluted product.
A conservative bias not often considered is that many workers wear underwear. By adding another layer of clothing (which is not included in the estimates of protection when estimating exposure from PD), the true dermal dose is reduced by up to 10-fold to the body regions covered by underwear that represent approximately half the total body surface area.
Biomonitoring for some pesticides is conservative, because the workers (especially reentry, but also M/L and applicators or reentering consumers) can contact the prehydrolyzed pesticide. A pertinent example is chlorpyrifos and hydrolysis to TCP. The TCP can probably be absorbed through the skin at a rate equal to or greater than the parent chlorpyrifos based on structural similarity to triclopyr (Carmichael et al., 1989; Barr and Angerer, 2006) . In some studies (e.g., , the background was not subtracted from daily collection of urine, also making those results conservative.
Biomonitoring data have been used historically as validation of PD. However, biomonitoring extrapolated to dermal dose may tend to overestimate handler dermal exposure for two reasons (Duggan et al., 2003) .
The biomonitored moiety typically representing a hydrolysis product of the parent for example, chlorpyrifos can have greater environmental persistence, allowing more contact by humans. Biomonitoring integrates all routes of exposure including dietary, non-dietary ingestion, incidental contact, inhalation, and dermal. The non-dietary ingestion during and after PD monitoring and incidental contact with contaminated machinery following PD monitoring both contribute unknown but potentially significant biomonitored exposure.
Conclusions
Use of PD in the 1950s through 1970s was instrumental in producing a significant reduction in acute pesticide illness in both handlers and reentry workers (Maddy et al., 1990) based on rudimentary knowledge of routes of exposure and particular regions of the body that tended to be the most highly exposed (e.g., hands). Beginning in the 1980s, the quantitative risk assessment paradigm adopted by regulators required not just preventing acute illness, but also proving quantitatively that exposures would not approach the toxicological no-effect level. This change in the risk paradigm required a change in the way PD measurements were made to reflect the refinements in dose estimates that were required.
Because it is difficult to isolate and validate particular dermal dosimetry methods, the best validation is a comparison of the absorbed dose derived from the sum of PD methods against the biomonitored dose. The data examined (both proprietary and public) demonstrate an excellent correlation between PD and biomonitoring. PD as a measure of dosage appears to be consistent with biomonitoring with no bias, that is, there is no tendency to over-or underestimate exposure.
In this paper, 14 concurrent or consecutive PD-biomonitoring studies were quantitatively evaluated and included 18 different methods of application or reentry scenarios for eight different active ingredients for which measured human kinetics and dermal absorption data existed. This evaluation demonstrated that the total absorbed dose (or daily dosage) estimated using PD for important handler and reentry scenarios is generally similar to the measurements for those same scenarios made using human urinary biomonitoring methods. Further, this is strongly supported by statistical analysis of individual worker PD: biomonitoring ratio and variance within and between studies. The PD techniques currently employed yield a reproducible, standard methodology that accurately and reliably quantifies exposure and does not underestimate daily absorbed dose. On the basis of these observations, PD has been successfully validated by biomonitoring.
